Loading...

Scilex Holding Company

SCLXNASDAQ
Healthcare
Drug Manufacturers - General
$11.96
$1.24(11.57%)

Scilex Holding Company (SCLX) Company Profile & Overview

Explore Scilex Holding Company’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Scilex Holding Company (SCLX) Company Profile & Overview

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

SectorHealthcare
IndustryDrug Manufacturers - General
CEOJaisim Shah

Contact Information

650-516-4310
960 San Antonio Road, Palo Alto, CA, 94303

Company Facts

115 Employees
IPO DateMar 5, 2021
CountryUS
Actively Trading

Frequently Asked Questions

;